TSRX down 7% from this morning's open high when TRSX's top line comparative results were very positive and the drug has a much better safety profile? Durata's top line results were less than lack luster.2.4 fall out rate compared to 1.9% for older Vanco& Linz
In their clinical trial, the drug-related treatment-emergent adverse event rate reported adverse events for Durata's data as nausea, diarrhea, vomiting, pruritus and headache. Discontinuations due to treatment emergent adverse events where higher with Durata's than with comparative existing antibiotics.
DRTX with dalbavancin a much less attractive candidate in the game, less money and no backer such as Bayer, far less shorts and their SP is $8.87 and popped to $10.40 on Trius +ve news last Monday kinda makes you wonder why TSRX never had more significant spike in price. Just goes to show you without a greedy MM manipulating the SP downwards, your much better drug company could be much higher in price.